Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens
1991

T Cell Activation After Monoclonal Antibody Therapy

Sample size: 13 publication Evidence: moderate

Author Information

Author(s): C. Kosmas, A.A. Epenetos, N.S. Courtenay-Luck

Primary Institution: Imperial Cancer Research Fund Oncology Group, Royal Postgraduate Medical School, Hammersmith Hospital

Hypothesis

Do patients receiving murine monoclonal antibody therapy develop T cells that can respond to these antibodies as antigens?

Conclusion

Murine monoclonal antibodies can lead to the generation of T cells that recognize these antibodies as antigens.

Supporting Evidence

  • 11 out of 13 patients showed increased T cell proliferation after therapy.
  • The mean stimulation index in post-therapy patients was significantly higher than in pre-therapy patients.
  • Patients receiving two courses of MAb treatment had a significant increase in T cell proliferation.

Takeaway

When patients with cancer receive special antibodies, their immune system can learn to recognize these antibodies and respond better to them.

Methodology

The study involved obtaining peripheral blood mononuclear cells from patients and testing T cell proliferation in response to murine monoclonal antibodies.

Limitations

The study had a small sample size and variability in T cell responses over time.

Participant Demographics

Patients included 12 with stage III or IV ovarian carcinoma and 1 with malignant pleural effusion; median age was 63 years.

Statistical Information

P-Value

p<0.005

Statistical Significance

p<0.005

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication